5-Amino-1MQ Research

What is 5-Amino-1MQ and How Does It Work?

5-Amino-1MQ, chemically known as 5-Amino-1-Methyl-Quinolinium, is a small-molecule synthetic compound designed to selectively inhibit the enzyme nicotinamide N-methyltransferase (NNMT). This enzyme catalyzes the methylation of nicotinamide, a form of vitamin B3, converting it to N1-methylnicotinamide. By inhibiting NNMT, 5-Amino-1MQ redirects nicotinamide metabolism toward NAD+ synthesis through the salvage pathway rather than its elimination as urinary metabolite.

The rationale for NNMT inhibition stems from metabolic research demonstrating that elevated NNMT activity is associated with impaired fat oxidation, reduced metabolic flexibility, and obesity-related phenotypes in rodent models. NAD+, a critical coenzyme for cellular energy metabolism and redox reactions, plays central roles in mitochondrial function, sirtuins activation, and metabolic regulation. By boosting NAD+ availability, 5-Amino-1MQ theoretically enhances cellular bioenergetics and metabolic health.

Original Discovery and Development

5-Amino-1MQ emerged from research programs at Caltech and collaborating institutions focused on NNMT biology and metabolic disease. The compound was initially synthesized and characterized as a potent NNMT inhibitor in the mid-2010s, with intellectual property protection filed through various patent applications. Early chemical optimization work identified 5-Amino-1MQ as one of the most selective and bioavailable NNMT inhibitors compared to first-generation candidates, making it suitable for both in vitro and in vivo research applications.

The scientific foundation for NNMT inhibition as a therapeutic strategy came from observations that NNMT is upregulated in adipose tissue of obese humans and rodents, and that genetic deletion or pharmacological inhibition of NNMT in mice leads to improved glucose tolerance, increased energy expenditure, and resistance to diet-induced obesity. These preclinical results motivated the development of potent, drug-like NNMT inhibitors for further investigation.

Key Preclinical Studies and Evidence

The most frequently cited preclinical study is the work by Neelakantan et al. (2022), published in peer-reviewed journals, which investigated the metabolic effects of NNMT inhibition using 5-Amino-1MQ in a diet-induced obesity model. This study demonstrated that 5-Amino-1MQ administration resulted in reduced body weight gain, decreased fat mass accumulation, improved glucose tolerance, and enhanced insulin sensitivity compared to vehicle-treated controls. Importantly, the study showed that these metabolic improvements were accompanied by increased whole-body energy expenditure and enhanced fat oxidation capacity in treated animals.

Kannt et al. and collaborators have published multiple studies characterizing NNMT inhibitors, including 5-Amino-1MQ, with respect to their pharmacological properties, selectivity profiles, and metabolic effects. These studies confirmed that 5-Amino-1MQ is a highly selective NNMT inhibitor with favorable pharmacokinetic properties, achieving good oral bioavailability in rodents and achieving target engagement in relevant tissues. The studies documented dose-dependent effects on NAD+ metabolism and associated metabolic phenotypes.

Additional preclinical research has examined the effects of NNMT inhibition on mitochondrial function, demonstrating that 5-Amino-1MQ treatment enhances mitochondrial oxidative capacity and increases markers of mitochondrial biogenesis. Studies have also shown that NNMT inhibition can modulate immune cell function and reduce inflammatory markers in obesity models, suggesting mechanisms beyond direct metabolic effects.

In Vitro Evidence Versus In Vivo Evidence

In vitro studies with 5-Amino-1MQ have demonstrated its ability to inhibit recombinant human NNMT enzyme with high potency and selectivity, with IC50 values typically in the nanomolar to low micromolar range depending on assay conditions. Cell-based assays using differentiated adipocytes, hepatocytes, and myocytes have shown that NNMT inhibition enhances NAD+-dependent pathways, including SIRT1 and SIRT3 signaling, which are associated with metabolic health and cellular stress resistance.

In vivo evidence from mouse models is substantially more extensive than human data. Rodent studies consistently show beneficial effects of NNMT inhibition on body composition, glucose homeostasis, and energy expenditure. However, these studies are often conducted using lean and metabolically characterized inbred mouse strains, which may not fully recapitulate the heterogeneity and complexity of human metabolism. Species differences in NNMT tissue distribution, enzyme kinetics, and metabolic regulation between rodents and humans introduce considerations for translational validity.

The gap between compelling in vitro and rodent in vivo evidence and limited human data represents a critical knowledge gap in 5-Amino-1MQ research. While the mechanistic basis for metabolic benefits is biologically plausible, human clinical data are necessary to confirm that these effects translate to meaningful health improvements in diverse human populations.

Proposed Mechanisms of Action

The primary proposed mechanism of 5-Amino-1MQ is inhibition of NNMT, leading to increased NAD+ availability and enhanced NAD+-dependent enzyme activity. SIRT1, SIRT3, and SIRT6 are key targets of increased NAD+ availability, and activation of these sirtuins is associated with improved metabolic health, enhanced mitochondrial function, and potential longevity benefits in model organisms.

Secondary mechanisms may include indirect metabolic effects mediated by changes in adipose tissue inflammation, immune cell polarization, and adipokine signaling. Some research suggests that NNMT inhibition can promote browning of white adipose tissue, increasing the proportion of thermogenic brown adipocytes, which would contribute to increased energy expenditure and improved metabolic health.

Additionally, enhanced NAD+ availability may improve mitochondrial function through increased activity of NAD+-dependent deacetylases and ADP-ribosyl transferases involved in mitochondrial protein homeostasis and quality control. These mechanisms could collectively contribute to the metabolic improvements observed in preclinical models.

Clinical Trial Pipeline and Status

As of April 2026, 5-Amino-1MQ has not been approved by any regulatory authority for human use, and the number of registered clinical trials remains limited compared to other metabolic compounds. Several companies have initiated or completed early-phase clinical studies to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers and patients with metabolic disorders. These Phase I and Phase II trials have generally reported acceptable safety profiles and target engagement in human subjects.

Information about specific trial designs, enrollment status, and preliminary results varies in availability. Some trial data may be restricted to academic publications, regulatory filings, or company press releases. Researchers interested in the latest clinical development status should consult ClinicalTrials.gov and company websites for current information about ongoing or planned studies.

The typical development pathway for NNMT inhibitors includes Phase I safety and pharmacokinetics studies, Phase II efficacy and dose-finding studies in relevant patient populations (such as obese or type 2 diabetic subjects), and Phase III confirmatory efficacy and safety trials. As of the current date, 5-Amino-1MQ appears to be in relatively early stages of clinical development, with most publicly available data coming from preclinical studies and early human safety assessments.

Critical Research Gaps and Unknowns

Several significant research gaps remain regarding 5-Amino-1MQ. First, long-term human safety and efficacy data are lacking. While preclinical toxicology studies have generally been reassuring, chronic dosing in humans over months or years remains unstudied, meaning potential long-term adverse effects are unknown.

Second, the optimal dosing regimen in humans has not been established through comparative clinical trials. Preclinical dosing is often normalized to body weight or adjusted for pharmacokinetic scaling, but translation to clinically relevant human doses requires robust dose-escalation and pharmacodynamic studies.

Third, the relative contribution of different proposed mechanisms (NNMT inhibition per se, NAD+ pathway activation, mitochondrial effects, immune modulation, adipose tissue remodeling) to the overall metabolic phenotype in humans remains unclear. This mechanistic understanding is important for predicting efficacy in specific patient populations and identifying potential responders versus non-responders.

Fourth, head-to-head comparisons of NNMT inhibitors with other metabolic compounds or proven weight-loss pharmacotherapies are absent. Understanding how 5-Amino-1MQ's effects compare to metformin, GLP-1 agonists, or other established interventions would be valuable for contextualizing its therapeutic potential.

Finally, the impact of genetic variation in NNMT, NAD+ metabolism genes, and metabolic pathways on individual response to 5-Amino-1MQ is not yet characterized. Pharmacogenomic studies could identify subpopulations most likely to benefit from treatment.

Comparison to Other Weight Loss and Metabolic Peptides

5-Amino-1MQ is often discussed alongside other research compounds targeting metabolic improvement, including other NAD+-boosting agents, mitochondrial modulators, and metabolic peptides like AOD-9604, Tesamorelin, and Ipamorelin. Unlike many peptides which are synthetic versions of endogenous hormones or fragments thereof, 5-Amino-1MQ is a small molecule enzyme inhibitor with a different mechanism of action.

AOD-9604, a C-terminal fragment of human growth hormone, has shown metabolic effects in some clinical trials but remains investigational. Tesamorelin and Ipamorelin are growth hormone secretagogues with documented effects on body composition but different targets and mechanisms compared to NNMT inhibition. NAD+ precursors like NMN and NR have gained attention in longevity research but work through different metabolic pathways than direct NNMT inhibition.

Compared to these alternatives, 5-Amino-1MQ offers a targeted approach to enhancing NAD+ availability through salvage pathway optimization rather than supplementation, and it has not yet achieved the clinical evidence base of established weight-loss medications. The evidence quality is thus lower than for approved pharmacotherapies but potentially comparable to many other investigational metabolic compounds in early development.

Regulatory Status and Current Availability

5-Amino-1MQ is not approved by the FDA, EMA, or other major regulatory agencies for use in humans. It is classified as a research chemical and is typically available through specialized research chemical suppliers, often marketed as "for research purposes only" or "not for human consumption."

This regulatory status means that 5-Amino-1MQ is not manufactured under the stringent quality controls applied to approved pharmaceuticals, manufacturing standards vary significantly across suppliers, and purity, stability, and contaminant testing are not guaranteed to pharmaceutical standards.

The compound is not scheduled or controlled under most national drug scheduling systems, meaning possession for personal use or distribution is not directly criminalized in most jurisdictions, though the intended use and specific jurisdictional laws should be verified.

Future Research Directions and Outlook

The future of 5-Amino-1MQ research likely involves several key directions. First, advancement of clinical development through completion of Phase II and initiation of Phase III efficacy trials in larger, more diverse patient populations will provide critical evidence regarding real-world metabolic benefits. Second, mechanistic studies dissecting the relative contributions of NNMT inhibition, NAD+ pathway activation, and downstream metabolic effects will refine understanding of how this compound affects human physiology.

Third, combination studies examining whether 5-Amino-1MQ provides additive or synergistic effects when combined with other metabolic interventions (exercise, dietary modification, other pharmacotherapies) could establish its role within comprehensive metabolic management strategies. Fourth, long-term safety and tolerability monitoring will be essential for establishing its risk-benefit profile relative to existing metabolic therapies.

Finally, development of superior second-generation NNMT inhibitors with improved potency, selectivity, tissue penetration, or reduced off-target effects may yield compounds with superior clinical profiles. The current compounds represent first-generation tools for exploring NNMT inhibition, and optimization is ongoing across the industry.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions